Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.51 USD
+0.03 (2.03%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $1.49 -0.02 (-1.32%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
KPTI 1.51 +0.03(2.03%)
Will KPTI be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KPTI
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Other News for KPTI
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)
Cantor sees strong year ahead for oncology M&A
Cantor Fitzgerald sees strong year ahead for oncology M&A
Big Pharma patent cliffs seen fueling oncology M&A this year
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences